We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron’s Antibody Cocktail Shows Success in Preventing COVID-19 in Phase 3 Study
Regeneron’s Antibody Cocktail Shows Success in Preventing COVID-19 in Phase 3 Study
In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine.